메뉴 바로가기 본문 바로가기
Technology Advanced liquid biopsy technology for
cancer detection & monitoring

Blood-based liquid biopsy is a minimally invasive test for cancer diagnosis that requires a simple blood draw.
It has recently risen as a possible substitute for tissue biopsy which includes a surgical procedure to obtain a piece of tumor tissue for analysis.
The AlphaLiquid® series is an advanced liquid biopsy platform that utilizes IMB Dx’s optimized biochemical technology along
with Next Generation Sequencing, as well as AI-based bioinformatic pipeline.

500% increase in experimental efficiency with statistical models applied

IMB Dx’s proprietary UniqSeq® technology allows cancer diagnosis with only trace amount of tumor DNA, through uniform DNA amplification at much higher efficiency than previously done.

High Analytical Performance 99%+ sensitivity, specificity

IMB Dx’s proprietary AI-driven analysis pipeline aims to build a Big Data system that evolves through constant accumulation of genomic information obtained from our services.
With this analyzed data, we can provide a personalized genome · epigenome mutational profile along with the most appropriate treatment options for the patient.

  • Limit of
    Detection
    > 0.1%
  • Sensitivity > 99%
  • Specificity > 99%
Clinically validated technology – Accurate detection of
genomic · epigenomic
mutations of
tumor in clinical trial cases -

We have analyzed over 2000 samples of cancer patients from major hospitals within Korea. These results are currently being utilized for diagnosis and monitoring in clinical settings.

Cumulative # of clinical
samples analyzed
2,000 +